share_log

CORRESP: CORRESP

CORRESP: CORRESP

CORRESP：信函
美股SEC公告 ·  2024/09/10 10:33

Moomoo AI 已提取核心信息

ZyVersa Therapeutics, Inc. has officially requested the U.S. Securities and Exchange Commission (SEC) to declare its Registration Statement on Form S-3 effective as of September 9, 2024, at 5:00 p.m. Eastern Time. The request, made under Rule 461 of the Securities Act of 1933, was submitted through a correspondence filed via EDGAR. ZyVersa Therapeutics, located at 2200 N. Commerce Parkway, Suite 208, Weston, Florida, has indicated that the effective date and time are subject to change if the company provides prior notification to the SEC. The company's Chief Executive Officer, Stephen C. Glover, signed the request, and any inquiries regarding this matter are to be directed to Faith L. Charles of Thompson Hine LLP, the company's outside counsel.
ZyVersa Therapeutics, Inc. has officially requested the U.S. Securities and Exchange Commission (SEC) to declare its Registration Statement on Form S-3 effective as of September 9, 2024, at 5:00 p.m. Eastern Time. The request, made under Rule 461 of the Securities Act of 1933, was submitted through a correspondence filed via EDGAR. ZyVersa Therapeutics, located at 2200 N. Commerce Parkway, Suite 208, Weston, Florida, has indicated that the effective date and time are subject to change if the company provides prior notification to the SEC. The company's Chief Executive Officer, Stephen C. Glover, signed the request, and any inquiries regarding this matter are to be directed to Faith L. Charles of Thompson Hine LLP, the company's outside counsel.
ZyVersa Therapeutics, Inc.已正式要求美国证券交易委员会（SEC）于2024年9月9日下午5:00（东部时间）生效其S-3表格的注册声明。该请求根据1933年证券法第461条规定，通过EDGAR提交的函电。位于佛罗里达州韦斯顿市2200 N. Commerce Parkway 208号的ZyVersa Therapeutics表示，生效日期和时间如需更改，公司将提前通知SEC。该公司首席执行官Stephen C. Glover签署了请求，有关此事的任何问题均需向该公司的外部法律顾问Thompson Hine LLP的Faith L. Charles提出。
ZyVersa Therapeutics, Inc.已正式要求美国证券交易委员会（SEC）于2024年9月9日下午5:00（东部时间）生效其S-3表格的注册声明。该请求根据1933年证券法第461条规定，通过EDGAR提交的函电。位于佛罗里达州韦斯顿市2200 N. Commerce Parkway 208号的ZyVersa Therapeutics表示，生效日期和时间如需更改，公司将提前通知SEC。该公司首席执行官Stephen C. Glover签署了请求，有关此事的任何问题均需向该公司的外部法律顾问Thompson Hine LLP的Faith L. Charles提出。
有用
没用

该公告为独立文件：

独立文件1

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Enveric Biosciences
    ENVB
    -- 2.3000
    Renovaro
    RENB
    -- 1.190
    Moolec Science
    MLEC
    -- 0.850
    Salarius Pharmaceuticals
    SLRX
    -- 1.4500
    Channel Therapeutics
    CHRO
    -- 2.230
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    科技巨头财报季如火如荼，英伟达压轴会表现如何？
    星期四， $亚马逊 (AMZN.US)$ 股价在公司报告第四季度调整后每股收益为1.86美元，预估为每股1.50美元，营业收入为1877.9亿，预估为1873.2亿后下跌。该公司预测第一季度的营业收入数字低于华尔街的预期，预测本季度最多为1550亿，而分析师希望为1580亿。 星 展开
    亚马逊盈利预告：猜测开盘价，获取奖励！